Wall Street Zen Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

A number of other research firms have also issued reports on COLL. Barclays reduced their price target on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

Collegium Pharmaceutical Stock Performance

COLL opened at $41.67 on Friday. The company has a market cap of $1.32 billion, a P/E ratio of 24.37 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $50.79. The firm’s 50-day moving average price is $46.50 and its 200-day moving average price is $42.09.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.20 by ($0.16). The firm had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.77 EPS. As a group, equities analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the sale, the executive vice president directly owned 103,613 shares in the company, valued at $4,991,038.21. This trade represents a 14.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the transaction, the director directly owned 52,629 shares of the company’s stock, valued at $2,475,141.87. The trade was a 6.49% decrease in their position. The SEC filing for this sale provides additional information. 2.51% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP grew its stake in Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after acquiring an additional 157,743 shares during the period. Vanguard Group Inc. raised its position in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares during the period. Renaissance Technologies LLC grew its position in shares of Collegium Pharmaceutical by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock valued at $74,883,000 after purchasing an additional 18,160 shares during the period. Janus Henderson Group PLC grew its position in shares of Collegium Pharmaceutical by 59.1% in the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after purchasing an additional 538,337 shares during the period. Finally, Principal Financial Group Inc. grew its position in shares of Collegium Pharmaceutical by 0.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after purchasing an additional 3,891 shares during the period.

Key Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Company expects strong growth for its lead product Jornay PM (targets ~31% Jornay revenue growth for 2026) and says it is advancing its pain portfolio—this supports longer‑term top‑line momentum. Article Title
• Positive Sentiment: Needham & Company slightly lowered its price target from $56 to $54 but maintained a “buy” rating, signaling analyst confidence that shares retain upside from current levels. Article Title
• Positive Sentiment: Collegium reported record full‑year net revenues of $780.6M (up 24% YoY) and Q4 net revenues of $205.4M (up 13% YoY), demonstrating solid revenue growth even as profit metrics were mixed. Article Title
• Neutral Sentiment: FY2026 revenue guidance was reiterated/updated to roughly $805M–$825M (in line with consensus), which reduces guidance risk but provides limited upside surprise potential. Article Title
• Neutral Sentiment: Collegium announced a partnership with Boston Legacy FC focused on sensory inclusion and ESG initiatives — positive for brand/ESG profile but limited near‑term financial impact. Article Title
• Neutral Sentiment: Several analyst writeups and a multi‑rating deep dive were published (collecting views from five analysts); useful for tracking sentiment but no consensus rating shock reported. Article Title
• Negative Sentiment: Earnings missed consensus: reported EPS was below expectations (reported $2.04 vs. ~$2.20 expected) and Q4 revenue slightly missed estimates—this is the primary driver of the share weakness today. Article Title
• Negative Sentiment: Earnings call / transcripts highlighted the miss and prompted investor questions on cadence and margins—market reaction to the tone of the call amplified selling pressure. Article Title
• Neutral Sentiment: Short‑interest data posted for February appears to contain errors (reported as 0 shares / NaN increase), so there’s no clear signal from short interest trends at this time. (Data likely unreliable.)
• Negative Sentiment: Trading showed elevated volume versus average as investors sold into the earnings print, contributing to the downward price move today.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.